Education
About Us
Working with TipRanks
Follow Us
Alpha Teknova (TKNO)
NASDAQ:TKNO
TKNO Stock Chart & Stats
$2.25
-$0.21(-2.33%)
At close: 4:00 PM EST
$2.25
-$0.21(-2.33%)
Day’s Range― - ―
52-Week Range$2.16 - $9.69
Previous CloseN/A
Volume51.57K
Average Volume (3M)318.88K
Market Cap
$120.44M
Enterprise Value$133.14M
Total Cash (Recent Filing)$3.20M
Total Debt (Recent Filing)$15.90M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Feb 26, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding53,529,175
10 Day Avg. Volume259,294
30 Day Avg. Volume318,881
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)4.74
Price to Sales (P/S)10.34
P/FCF Ratio-28.88
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue3.35
Enterprise Value/Gross Profit10.80
Enterprise Value/Ebitda-11.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market EnvironmentImproving biotech funding and a firmer pharmaceutical funding backdrop in 2026 can drive higher order activity and strengthen Teknova's sales pipeline.
Revenue DiversificationDiversified revenue exposure across Lab Essentials and other product lines reduces reliance on any single customer segment and enhances resilience amid biotech funding swings.
Revenue GrowthTeknova's consecutive quarterly revenue increases indicate sustained demand for its lab products and support continued top-line momentum.
Bears Say
Clinical Solutions PerformanceClinical Solutions revenue shortfalls point to a slower recovery in that segment, which may damp overall revenue growth until demand normalizes.
Guidance And Valuation RiskManagement's more conservative outlook, alongside lowered analyst valuation assumptions, could limit upside and put pressure on the stock's valuation.
Margin VolatilityChoppy gross margin trends introduce uncertainty to profitability and could compress earnings if cost pressures or an unfavorable product mix persist.
Alpha Teknova News
TKNO FAQ
What was Alpha Teknova’s price range in the past 12 months?
Alpha Teknova lowest stock price was $2.15 and its highest was $9.69 in the past 12 months.
What is Alpha Teknova’s market cap?
Alpha Teknova’s market cap is $120.44M.
When is Alpha Teknova’s upcoming earnings report date?
Alpha Teknova’s upcoming earnings report date is Feb 26, 2026 which is in 17 days.
How were Alpha Teknova’s earnings last quarter?
Alpha Teknova released its earnings results on Nov 06, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.094 by $0.014.
Is Alpha Teknova overvalued?
According to Wall Street analysts Alpha Teknova’s price is currently Overvalued.
Does Alpha Teknova pay dividends?
Alpha Teknova does not currently pay dividends.
What is Alpha Teknova’s EPS estimate?
Alpha Teknova’s EPS estimate is -0.09.
How many shares outstanding does Alpha Teknova have?
Alpha Teknova has 53,529,175 shares outstanding.
What happened to Alpha Teknova’s price movement after its last earnings report?
Alpha Teknova reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.094. Following the earnings report the stock price went down -2.079%.
Which hedge fund is a major shareholder of Alpha Teknova?
Currently, no hedge funds are holding shares in TKNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Teknova Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Increased
By 49.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 12.9%
Last 30 Days ▼ 12.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.12%
12-Months-Change
Fundamentals
Return on Equity
-22.79%
Trailing 12-Months
Asset Growth
-4.22%
Trailing 12-Months
Company Description
Alpha Teknova
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
TKNO Company Deck
TKNO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with consistent revenue growth driven by Lab Essentials products and operational improvements, but challenges persist in the Clinical Solutions segment and biopharma market. Despite these challenges, the company has made strategic investments to ensure long-term growth and improve operational efficiency.View all TKNO earnings summariesTKNO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
1.19% Insiders
1.88% Mutual Funds
3.86% Other Institutional Investors
91.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---